Global Dendritic Cell Cancer Vaccine Market Research Report 2022

Publisher Name :
Date: 14-Jul-2022
No. of pages: 100
Inquire Before Buying

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

- CreaVax

- Sipuleucel-T (Provenge)

- Others

Segment by Application

- Pediatrics

- Adults

By Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- - Philippines

- - Vietnam

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - U.A.E

By Company

- Activarti

- Argos Therapeutics

- SOTIO (Acquired by PPF Group)

- Bellicum Pharmaceuticals

- JW CreaGene

- DanDrit

- DCPrime

- Elios Therapeutics

- ImmunoCellular Therapeutics

- Kiromic

- Medigene

- Merck

- Northwest Biotherapeutics

- Immutep Limited

- Dendreon Corporation

- Oncobiomed

Global Dendritic Cell Cancer Vaccine Market Research Report 2022

Table of Contents
1 Dendritic Cell Cancer Vaccine Market Overview
1.1 Product Overview and Scope of Dendritic Cell Cancer Vaccine
1.2 Dendritic Cell Cancer Vaccine Segment by Type
1.2.1 Global Dendritic Cell Cancer Vaccine Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 CreaVax
1.2.3 Sipuleucel-T (Provenge)
1.2.4 Others
1.3 Dendritic Cell Cancer Vaccine Segment by Application
1.3.1 Global Dendritic Cell Cancer Vaccine Sales Comparison by Application: (2022-2028)
1.3.2 Pediatrics
1.3.3 Adults
1.4 Global Dendritic Cell Cancer Vaccine Market Size Estimates and Forecasts
1.4.1 Global Dendritic Cell Cancer Vaccine Revenue 2017-2028
1.4.2 Global Dendritic Cell Cancer Vaccine Sales 2017-2028
1.4.3 Dendritic Cell Cancer Vaccine Market Size by Region: 2017 Versus 2021 Versus 2028
2 Dendritic Cell Cancer Vaccine Market Competition by Manufacturers
2.1 Global Dendritic Cell Cancer Vaccine Sales Market Share by Manufacturers (2017-2022)
2.2 Global Dendritic Cell Cancer Vaccine Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Dendritic Cell Cancer Vaccine Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Dendritic Cell Cancer Vaccine Manufacturing Sites, Area Served, Product Type
2.5 Dendritic Cell Cancer Vaccine Market Competitive Situation and Trends
2.5.1 Dendritic Cell Cancer Vaccine Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Dendritic Cell Cancer Vaccine Players Market Share by Revenue
2.5.3 Global Dendritic Cell Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Dendritic Cell Cancer Vaccine Retrospective Market Scenario by Region
3.1 Global Dendritic Cell Cancer Vaccine Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Dendritic Cell Cancer Vaccine Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Dendritic Cell Cancer Vaccine Market Facts & Figures by Country
3.3.1 North America Dendritic Cell Cancer Vaccine Sales by Country
3.3.2 North America Dendritic Cell Cancer Vaccine Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Dendritic Cell Cancer Vaccine Market Facts & Figures by Country
3.4.1 Europe Dendritic Cell Cancer Vaccine Sales by Country
3.4.2 Europe Dendritic Cell Cancer Vaccine Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Dendritic Cell Cancer Vaccine Market Facts & Figures by Region
3.5.1 Asia Pacific Dendritic Cell Cancer Vaccine Sales by Region
3.5.2 Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Dendritic Cell Cancer Vaccine Market Facts & Figures by Country
3.6.1 Latin America Dendritic Cell Cancer Vaccine Sales by Country
3.6.2 Latin America Dendritic Cell Cancer Vaccine Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Dendritic Cell Cancer Vaccine Market Facts & Figures by Country
3.7.1 Middle East and Africa Dendritic Cell Cancer Vaccine Sales by Country
3.7.2 Middle East and Africa Dendritic Cell Cancer Vaccine Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Dendritic Cell Cancer Vaccine Historic Market Analysis by Type
4.1 Global Dendritic Cell Cancer Vaccine Sales Market Share by Type (2017-2022)
4.2 Global Dendritic Cell Cancer Vaccine Revenue Market Share by Type (2017-2022)
4.3 Global Dendritic Cell Cancer Vaccine Price by Type (2017-2022)
5 Global Dendritic Cell Cancer Vaccine Historic Market Analysis by Application
5.1 Global Dendritic Cell Cancer Vaccine Sales Market Share by Application (2017-2022)
5.2 Global Dendritic Cell Cancer Vaccine Revenue Market Share by Application (2017-2022)
5.3 Global Dendritic Cell Cancer Vaccine Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Activarti
6.1.1 Activarti Corporation Information
6.1.2 Activarti Description and Business Overview
6.1.3 Activarti Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Activarti Dendritic Cell Cancer Vaccine Product Portfolio
6.1.5 Activarti Recent Developments/Updates
6.2 Argos Therapeutics
6.2.1 Argos Therapeutics Corporation Information
6.2.2 Argos Therapeutics Description and Business Overview
6.2.3 Argos Therapeutics Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Argos Therapeutics Dendritic Cell Cancer Vaccine Product Portfolio
6.2.5 Argos Therapeutics Recent Developments/Updates
6.3 SOTIO (Acquired by PPF Group)
6.3.1 SOTIO (Acquired by PPF Group) Corporation Information
6.3.2 SOTIO (Acquired by PPF Group) Description and Business Overview
6.3.3 SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.3.4 SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Product Portfolio
6.3.5 SOTIO (Acquired by PPF Group) Recent Developments/Updates
6.4 Bellicum Pharmaceuticals
6.4.1 Bellicum Pharmaceuticals Corporation Information
6.4.2 Bellicum Pharmaceuticals Description and Business Overview
6.4.3 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Product Portfolio
6.4.5 Bellicum Pharmaceuticals Recent Developments/Updates
6.5 JW CreaGene
6.5.1 JW CreaGene Corporation Information
6.5.2 JW CreaGene Description and Business Overview
6.5.3 JW CreaGene Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.5.4 JW CreaGene Dendritic Cell Cancer Vaccine Product Portfolio
6.5.5 JW CreaGene Recent Developments/Updates
6.6 DanDrit
6.6.1 DanDrit Corporation Information
6.6.2 DanDrit Description and Business Overview
6.6.3 DanDrit Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.6.4 DanDrit Dendritic Cell Cancer Vaccine Product Portfolio
6.6.5 DanDrit Recent Developments/Updates
6.7 DCPrime
6.6.1 DCPrime Corporation Information
6.6.2 DCPrime Description and Business Overview
6.6.3 DCPrime Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.4.4 DCPrime Dendritic Cell Cancer Vaccine Product Portfolio
6.7.5 DCPrime Recent Developments/Updates
6.8 Elios Therapeutics
6.8.1 Elios Therapeutics Corporation Information
6.8.2 Elios Therapeutics Description and Business Overview
6.8.3 Elios Therapeutics Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Elios Therapeutics Dendritic Cell Cancer Vaccine Product Portfolio
6.8.5 Elios Therapeutics Recent Developments/Updates
6.9 ImmunoCellular Therapeutics
6.9.1 ImmunoCellular Therapeutics Corporation Information
6.9.2 ImmunoCellular Therapeutics Description and Business Overview
6.9.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.9.4 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Product Portfolio
6.9.5 ImmunoCellular Therapeutics Recent Developments/Updates
6.10 Kiromic
6.10.1 Kiromic Corporation Information
6.10.2 Kiromic Description and Business Overview
6.10.3 Kiromic Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Kiromic Dendritic Cell Cancer Vaccine Product Portfolio
6.10.5 Kiromic Recent Developments/Updates
6.11 Medigene
6.11.1 Medigene Corporation Information
6.11.2 Medigene Dendritic Cell Cancer Vaccine Description and Business Overview
6.11.3 Medigene Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Medigene Dendritic Cell Cancer Vaccine Product Portfolio
6.11.5 Medigene Recent Developments/Updates
6.12 Merck
6.12.1 Merck Corporation Information
6.12.2 Merck Dendritic Cell Cancer Vaccine Description and Business Overview
6.12.3 Merck Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Merck Dendritic Cell Cancer Vaccine Product Portfolio
6.12.5 Merck Recent Developments/Updates
6.13 Northwest Biotherapeutics
6.13.1 Northwest Biotherapeutics Corporation Information
6.13.2 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Description and Business Overview
6.13.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Product Portfolio
6.13.5 Northwest Biotherapeutics Recent Developments/Updates
6.14 Immutep Limited
6.14.1 Immutep Limited Corporation Information
6.14.2 Immutep Limited Dendritic Cell Cancer Vaccine Description and Business Overview
6.14.3 Immutep Limited Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Immutep Limited Dendritic Cell Cancer Vaccine Product Portfolio
6.14.5 Immutep Limited Recent Developments/Updates
6.15 Dendreon Corporation
6.15.1 Dendreon Corporation Corporation Information
6.15.2 Dendreon Corporation Dendritic Cell Cancer Vaccine Description and Business Overview
6.15.3 Dendreon Corporation Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Dendreon Corporation Dendritic Cell Cancer Vaccine Product Portfolio
6.15.5 Dendreon Corporation Recent Developments/Updates
6.16 Oncobiomed
6.16.1 Oncobiomed Corporation Information
6.16.2 Oncobiomed Dendritic Cell Cancer Vaccine Description and Business Overview
6.16.3 Oncobiomed Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Oncobiomed Dendritic Cell Cancer Vaccine Product Portfolio
6.16.5 Oncobiomed Recent Developments/Updates
7 Dendritic Cell Cancer Vaccine Manufacturing Cost Analysis
7.1 Dendritic Cell Cancer Vaccine Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Dendritic Cell Cancer Vaccine
7.4 Dendritic Cell Cancer Vaccine Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Dendritic Cell Cancer Vaccine Distributors List
8.3 Dendritic Cell Cancer Vaccine Customers
9 Dendritic Cell Cancer Vaccine Market Dynamics
9.1 Dendritic Cell Cancer Vaccine Industry Trends
9.2 Dendritic Cell Cancer Vaccine Market Drivers
9.3 Dendritic Cell Cancer Vaccine Market Challenges
9.4 Dendritic Cell Cancer Vaccine Market Restraints
10 Global Market Forecast
10.1 Dendritic Cell Cancer Vaccine Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Dendritic Cell Cancer Vaccine by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Dendritic Cell Cancer Vaccine by Type (2023-2028)
10.2 Dendritic Cell Cancer Vaccine Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Dendritic Cell Cancer Vaccine by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Dendritic Cell Cancer Vaccine by Application (2023-2028)
10.3 Dendritic Cell Cancer Vaccine Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Dendritic Cell Cancer Vaccine by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Dendritic Cell Cancer Vaccine by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Dendritic Cell Cancer Vaccine Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Dendritic Cell Cancer Vaccine Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Dendritic Cell Cancer Vaccine Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Dendritic Cell Cancer Vaccine Market Competitive Situation by Manufacturers in 2021
Table 5. Global Dendritic Cell Cancer Vaccine Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Dendritic Cell Cancer Vaccine Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Dendritic Cell Cancer Vaccine Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Dendritic Cell Cancer Vaccine Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Dendritic Cell Cancer Vaccine Average Price (USD/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Dendritic Cell Cancer Vaccine Manufacturing Sites and Area Served
Table 11. Manufacturers Dendritic Cell Cancer Vaccine Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Dendritic Cell Cancer Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dendritic Cell Cancer Vaccine as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Dendritic Cell Cancer Vaccine Sales by Region (2017-2022) & (K Units)
Table 16. Global Dendritic Cell Cancer Vaccine Sales Market Share by Region (2017-2022)
Table 17. Global Dendritic Cell Cancer Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Region (2017-2022)
Table 19. North America Dendritic Cell Cancer Vaccine Sales by Country (2017-2022) & (K Units)
Table 20. North America Dendritic Cell Cancer Vaccine Sales Market Share by Country (2017-2022)
Table 21. North America Dendritic Cell Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Dendritic Cell Cancer Vaccine Revenue Market Share by Country (2017-2022)
Table 23. Europe Dendritic Cell Cancer Vaccine Sales by Country (2017-2022) & (K Units)
Table 24. Europe Dendritic Cell Cancer Vaccine Sales Market Share by Country (2017-2022)
Table 25. Europe Dendritic Cell Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Dendritic Cell Cancer Vaccine Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Dendritic Cell Cancer Vaccine Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Dendritic Cell Cancer Vaccine Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Dendritic Cell Cancer Vaccine Revenue Market Share by Region (2017-2022)
Table 31. Latin America Dendritic Cell Cancer Vaccine Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Dendritic Cell Cancer Vaccine Sales Market Share by Country (2017-2022)
Table 33. Latin America Dendritic Cell Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Dendritic Cell Cancer Vaccine Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Dendritic Cell Cancer Vaccine Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Dendritic Cell Cancer Vaccine Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Dendritic Cell Cancer Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Dendritic Cell Cancer Vaccine Revenue Market Share by Country (2017-2022)
Table 39. Global Dendritic Cell Cancer Vaccine Sales by Type (2017-2022) & (K Units)
Table 40. Global Dendritic Cell Cancer Vaccine Sales Market Share by Type (2017-2022)
Table 41. Global Dendritic Cell Cancer Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Dendritic Cell Cancer Vaccine Revenue Share by Type (2017-2022)
Table 43. Global Dendritic Cell Cancer Vaccine Price by Type (2017-2022) & (USD/Unit)
Table 44. Global Dendritic Cell Cancer Vaccine Sales (K Units) by Application (2017-2022)
Table 45. Global Dendritic Cell Cancer Vaccine Sales Market Share by Application (2017-2022)
Table 46. Global Dendritic Cell Cancer Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Dendritic Cell Cancer Vaccine Revenue Share by Application (2017-2022)
Table 48. Global Dendritic Cell Cancer Vaccine Price by Application (2017-2022) & (USD/Unit)
Table 49. Activarti Corporation Information
Table 50. Activarti Description and Business Overview
Table 51. Activarti Dendritic Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 52. Activarti Dendritic Cell Cancer Vaccine Product
Table 53. Activarti Recent Developments/Updates
Table 54. Argos Therapeutics Corporation Information
Table 55. Argos Therapeutics Description and Business Overview
Table 56. Argos Therapeutics Dendritic Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 57. Argos Therapeutics Dendritic Cell Cancer Vaccine Product
Table 58. Argos Therapeutics Recent Developments/Updates
Table 59. SOTIO (Acquired by PPF Group) Corporation Information
Table 60. SOTIO (Acquired by PPF Group) Description and Business Overview
Table 61. SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 62. SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Product
Table 63. SOTIO (Acquired by PPF Group) Recent Developments/Updates
Table 64. Bellicum Pharmaceuticals Corporation Information
Table 65. Bellicum Pharmaceuticals Description and Business Overview
Table 66. Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 67. Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Product
Table 68. Bellicum Pharmaceuticals Recent Developments/Updates
Table 69. JW CreaGene Corporation Information
Table 70. JW CreaGene Description and Business Overview
Table 71. JW CreaGene Dendritic Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 72. JW CreaGene Dendritic Cell Cancer Vaccine Product
Table 73. JW CreaGene Recent Developments/Updates
Table 74. DanDrit Corporation Information
Table 75. DanDrit Description and Business Overview
Table 76. DanDrit Dendritic Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 77. DanDrit Dendritic Cell Cancer Vaccine Product
Table 78. DanDrit Recent Developments/Updates
Table 79. DCPrime Corporation Information
Table 80. DCPrime Description and Business Overview
Table 81. DCPrime Dendritic Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 82. DCPrime Dendritic Cell Cancer Vaccine Product
Table 83. DCPrime Recent Developments/Updates
Table 84. Elios Therapeutics Corporation Information
Table 85. Elios Therapeutics Description and Business Overview
Table 86. Elios Therapeutics Dendritic Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 87. Elios Therapeutics Dendritic Cell Cancer Vaccine Product
Table 88. Elios Therapeutics Recent Developments/Updates
Table 89. ImmunoCellular Therapeutics Corporation Information
Table 90. ImmunoCellular Therapeutics Description and Business Overview
Table 91. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 92. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Product
Table 93. ImmunoCellular Therapeutics Recent Developments/Updates
Table 94. Kiromic Corporation Information
Table 95. Kiromic Description and Business Overview
Table 96. Kiromic Dendritic Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 97. Kiromic Dendritic Cell Cancer Vaccine Product
Table 98. Kiromic Recent Developments/Updates
Table 99. Medigene Corporation Information
Table 100. Medigene Description and Business Overview
Table 101. Medigene Dendritic Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 102. Medigene Dendritic Cell Cancer Vaccine Product
Table 103. Medigene Recent Developments/Updates
Table 104. Merck Corporation Information
Table 105. Merck Description and Business Overview
Table 106. Merck Dendritic Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 107. Merck Dendritic Cell Cancer Vaccine Product
Table 108. Merck Recent Developments/Updates
Table 109. Northwest Biotherapeutics Corporation Information
Table 110. Northwest Biotherapeutics Description and Business Overview
Table 111. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 112. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Product
Table 113. Northwest Biotherapeutics Recent Developments/Updates
Table 114. Immutep Limited Corporation Information
Table 115. Immutep Limited Description and Business Overview
Table 116. Immutep Limited Dendritic Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 117. Immutep Limited Dendritic Cell Cancer Vaccine Product
Table 118. Immutep Limited Recent Developments/Updates
Table 119. Dendreon Corporation Corporation Information
Table 120. Dendreon Corporation Description and Business Overview
Table 121. Dendreon Corporation Dendritic Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 122. Dendreon Corporation Dendritic Cell Cancer Vaccine Product
Table 123. Dendreon Corporation Recent Developments/Updates
Table 124. Oncobiomed Corporation Information
Table 125. Oncobiomed Description and Business Overview
Table 126. Oncobiomed Dendritic Cell Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 127. Oncobiomed Dendritic Cell Cancer Vaccine Product
Table 128. Oncobiomed Recent Developments/Updates
Table 129. Production Base and Market Concentration Rate of Raw Material
Table 130. Key Suppliers of Raw Materials
Table 131. Dendritic Cell Cancer Vaccine Distributors List
Table 132. Dendritic Cell Cancer Vaccine Customers List
Table 133. Dendritic Cell Cancer Vaccine Market Trends
Table 134. Dendritic Cell Cancer Vaccine Market Drivers
Table 135. Dendritic Cell Cancer Vaccine Market Challenges
Table 136. Dendritic Cell Cancer Vaccine Market Restraints
Table 137. Global Dendritic Cell Cancer Vaccine Sales Forecast by Type (2023-2028) & (K Units)
Table 138. Global Dendritic Cell Cancer Vaccine Sales Market Share Forecast by Type (2023-2028)
Table 139. Global Dendritic Cell Cancer Vaccine Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 140. Global Dendritic Cell Cancer Vaccine Revenue Market Share Forecast by Type (2023-2028)
Table 141. Global Dendritic Cell Cancer Vaccine Sales Forecast by Application (2023-2028) & (K Units)
Table 142. Global Dendritic Cell Cancer Vaccine Sales Market Share Forecast by Application (2023-2028)
Table 143. Global Dendritic Cell Cancer Vaccine Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 144. Global Dendritic Cell Cancer Vaccine Revenue Market Share Forecast by Application (2023-2028)
Table 145. Global Dendritic Cell Cancer Vaccine Sales Forecast by Region (2023-2028) & (K Units)
Table 146. Global Dendritic Cell Cancer Vaccine Sales Market Share Forecast by Region (2023-2028)
Table 147. Global Dendritic Cell Cancer Vaccine Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 148. Global Dendritic Cell Cancer Vaccine Revenue Market Share Forecast by Region (2023-2028)
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Dendritic Cell Cancer Vaccine
Figure 2. Global Dendritic Cell Cancer Vaccine Market Share by Type in 2021 & 2028
Figure 3. CreaVax Product Picture
Figure 4. Sipuleucel-T (Provenge) Product Picture
Figure 5. Others Product Picture
Figure 6. Global Dendritic Cell Cancer Vaccine Market Share by Application in 2021 & 2028
Figure 7. Pediatrics
Figure 8. Adults
Figure 9. Global Dendritic Cell Cancer Vaccine Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 10. Global Dendritic Cell Cancer Vaccine Market Size (2017-2028) & (US$ Million)
Figure 11. Global Dendritic Cell Cancer Vaccine Sales (2017-2028) & (K Units)
Figure 12. Dendritic Cell Cancer Vaccine Sales Share by Manufacturers in 2021
Figure 13. Global Dendritic Cell Cancer Vaccine Revenue Share by Manufacturers in 2021
Figure 14. The Global 5 and 10 Largest Dendritic Cell Cancer Vaccine Players: Market Share by Revenue in 2021
Figure 15. Dendritic Cell Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 16. Global Dendritic Cell Cancer Vaccine Sales Market Share by Region (2017-2022)
Figure 17. Global Dendritic Cell Cancer Vaccine Sales Market Share by Region in 2021
Figure 18. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Region (2017-2022)
Figure 19. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Region in 2021
Figure 20. U.S. Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 21. Canada Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. Germany Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. France Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. U.K. Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Italy Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. Russia Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. China Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. Japan Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. South Korea Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. India Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. Australia Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Taiwan Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Indonesia Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Thailand Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Malaysia Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Philippines Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Vietnam Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Mexico Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Brazil Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Argentina Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Turkey Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Saudi Arabia Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. U.A.E Dendritic Cell Cancer Vaccine Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Sales Market Share of Dendritic Cell Cancer Vaccine by Type (2017-2022)
Figure 45. Manufacturing Cost Structure of Dendritic Cell Cancer Vaccine
Figure 46. Manufacturing Process Analysis of Dendritic Cell Cancer Vaccine
Figure 47. Dendritic Cell Cancer Vaccine Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
  • Global BCG Vaccine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 96
    According to our LPI (LP Information) latest study, the global BCG Vaccine market size was valued at US$ 365.6 million in 2023. With growing demand in downstream market, the BCG Vaccine is forecast to a readjusted size of US$ 542.8 million by 2030 with a CAGR of 5.8% during review period. The research report highlights the growth potential of the global BCG Vaccine market. BCG Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing cost......
  • Global Peptide Cancer Vaccine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 115
    According to our LPI (LP Information) latest study, the global Peptide Cancer Vaccine market size was valued at US$ 535 million in 2023. With growing demand in downstream market, the Peptide Cancer Vaccine is forecast to a readjusted size of US$ 1978.2 million by 2030 with a CAGR of 20.5% during review period. The research report highlights the growth potential of the global Peptide Cancer Vaccine market. Peptide Cancer Vaccine are expected to show stable growth in the future market. How......
  • Global Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global Cancer Vaccine market: According to our latest research, the global Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Cancer Vaccine market was estimated at USD 7198.2 million, and it's anticipated to reach USD 33936.62 million in 2028, with a CAGR of 29.49% during the forecast years. A cancer vaccine is a type of immunotherapy that boost the body's natural defenses by stimulating the immune system to recognize and cur......
  • Global Lung Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 12-Dec-2023        Price: US 3380 Onwards        Pages: 102
    Market Overview of Global Lung Cancer Vaccines market: According to our latest research, the global Lung Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Lung Cancer Vaccines market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Lung Cancer Vaccines,A cancer vaccine for lung cance This report covers a research time span from 2018 to 2028, and ......
  • Global Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 07-Dec-2023        Price: US 3380 Onwards        Pages: 105
    Market Overview of Global Cancer Vaccines market: According to our latest research, the global Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Cancer Vaccines market was estimated at USD 5773.14 million, and it's anticipated to reach USD 15406.41 million in 2028, with a CAGR of 17.77% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Vacci......
  • Global Dendritic Cell Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 110
    Market Overview of Global Dendritic Cell Cancer Vaccine market: According to our latest research, the global Dendritic Cell Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Dendritic Cell Cancer Vaccine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Dendritic cells (DC) are one of the major antigen presenting cells found in lymphoid organs. The main fu......
  • Global BCG Vaccine Market Research Report 2023, Forecast to 2028
    Published: 14-Nov-2023        Price: US 2680 Onwards        Pages: 135
    BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......
  • Global BCG Vaccine Professional Survey Report 2023, Forecast to 2028
    Published: 14-Nov-2023        Price: US 3280 Onwards        Pages: 105
    BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......
  • Infectious Vaccine Collaboration and Licensing Deals 2016-2023
    Published: 01-Nov-2023        Price: US 3995 Onwards        Pages: 300
    Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious vaccine deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of infectious vaccine deals from 2016 to 2023. The report provides a detailed understanding and analysis of how and why companies enter infectious vaccine deals. These deals tend to be multicomponent, starting with......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs